Mixed IgG Fc immune complexes exhibit blended binding profiles and refine FcR affinity estimates.


Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
15 Feb 2023
Historique:
entrez: 24 2 2023
pubmed: 25 2 2023
medline: 25 2 2023
Statut: epublish

Résumé

Immunoglobulin (Ig)G antibodies coordinate immune effector responses by selectively binding to target antigens and then interacting with various effector cells via the Fcγ receptors. The Fc domain of IgG can promote or inhibit distinct effector responses across several different immune cell types through variation based on subclass and Fc domain glycosylation. Extensive characterization of these interactions has revealed how the inclusion of certain Fc subclasses or glycans results in distinct immune responses. During an immune response, however, IgG is produced with mixtures of Fc domain properties, so antigen-IgG immune complexes are likely to almost always be comprised of a combination of Fc forms. Whether and how this mixed composition influences immune effector responses has not been examined. Here, we measured Fcγ receptor binding to immune complexes of mixed Fc domain composition. We found that the binding properties of the mixed-composition immune complexes fell along a continuum between those of the corresponding pure cases. Binding quantitatively matched a mechanistic binding model, except for several low-affinity interactions mostly involving IgG2. We found that the affinities of these interactions are different than previously reported, and that the binding model could be used to provide refined estimates of these affinities. Finally, we demonstrated that the binding model can predict effector-cell elicited platelet depletion in humanized mice, with the model inferring the relevant effector cell populations. Contrary to the previous view in which IgG2 poorly engages with effector populations, we observe appreciable binding through avidity, but insufficient amounts to observe immune effector responses. Overall, this work demonstrates a quantitative framework for reasoning about effector response regulation arising from IgG of mixed Fc composition. The binding behavior of mixed Fc immune complexes is a blend of the binding properties for each constituent IgG species.An equilibrium, multivalent binding model can be generalized to incorporate immune complexes of mixed Fc composition.Particularly for low-affinity IgG-Fcγ receptor interactions, immune complexes provide better estimates of affinities.The FcγR binding model predicts effector-elicited cell clearance in humanized mice.

Identifiants

pubmed: 36824734
doi: 10.1101/2023.02.15.528730
pmc: PMC9949097
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : U01 AI148119
Pays : United States

Commentaires et corrections

Type : UpdateIn

Références

Eur J Pharm Biopharm. 2016 Mar;100:94-100
pubmed: 26775146
Front Immunol. 2020 Feb 05;11:118
pubmed: 32117269
Science. 2005 Dec 2;310(5753):1510-2
pubmed: 16322460
J Immunol. 2007 Sep 1;179(5):2815-23
pubmed: 17709495
Cell Rep. 2015 Oct 20;13(3):610-620
pubmed: 26456831
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
Front Immunol. 2013 Aug 09;4:235
pubmed: 23950757
Cell Rep. 2014 Apr 10;7(1):236-48
pubmed: 24685130
Front Immunol. 2017 Aug 02;8:877
pubmed: 28824618
J Immunol. 2013 Apr 15;190(8):4315-23
pubmed: 23509345
Cancer Immun. 2012;12:13
pubmed: 22896758
Rapid Commun Mass Spectrom. 2008;22(1):29-40
pubmed: 18050193
J Am Chem Soc. 2020 May 27;142(21):9653-9660
pubmed: 32338896
Biophys J. 2001 Nov;81(5):2547-57
pubmed: 11606269
Cell Rep Med. 2021 Sep 01;2(9):100386
pubmed: 34622227
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
Front Immunol. 2019 Apr 08;10:697
pubmed: 31024542
Math Biosci. 2021 Dec;342:108714
pubmed: 34637774
N Engl J Med. 1980 Jul 24;303(4):178-82
pubmed: 6966763
MAbs. 2017 Jul;9(5):767-773
pubmed: 28463043
Cell. 2018 Jun 28;174(1):131-142.e13
pubmed: 29958103
J Allergy Clin Immunol. 2022 Nov;150(5):999-1010
pubmed: 36336400
J Clin Invest. 2013 Dec;123(12):5098-103
pubmed: 24177426
J Clin Immunol. 2013 Jan;33 Suppl 1:S4-8
pubmed: 22948744
Cell Syst. 2018 Jul 25;7(1):41-48.e5
pubmed: 29960887
Integr Biol (Camb). 2021 Dec 30;13(11):269-282
pubmed: 34931243
Immunity. 2011 Dec 23;35(6):932-44
pubmed: 22169040
Protein Cell. 2018 Jan;9(1):47-62
pubmed: 28597152
Cell. 2015 Nov 5;163(4):988-98
pubmed: 26544943
Science. 2013 May 10;340(6133):751-6
pubmed: 23661761

Auteurs

Zhixin Cyrillus Tan (Z)

Bioinformatics Interdepartmental Program, University of California, Los Angeles (UCLA).

Anja Lux (A)

Department of Genetics, Friedrich-Alexander-University of Erlangen-Nürnberg.

Markus Biburger (M)

Department of Genetics, Friedrich-Alexander-University of Erlangen-Nürnberg.

Prabha Varghese (P)

Department of Genetics, Friedrich-Alexander-University of Erlangen-Nürnberg.

Stephen Lees (S)

Department of Bioengineering, UCLA.

Falk Nimmerjahn (F)

Department of Genetics, Friedrich-Alexander-University of Erlangen-Nürnberg.

Aaron S Meyer (AS)

Bioinformatics Interdepartmental Program, University of California, Los Angeles (UCLA).
Department of Bioengineering, UCLA.
Jonsson Comprehensive Cancer Center, UCLA.
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA.

Classifications MeSH